A Multicenter Open-label Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
Latest Information Update: 28 Jun 2025
At a glance
- Drugs Dupilumab (Primary)
- Indications Prurigo nodularis
- Focus Pharmacokinetics; Registrational
- Sponsors Sanofi
Most Recent Events
- 30 Apr 2024 Status changed from not yet recruiting to recruiting.
- 11 Mar 2024 New trial record